Journal ArticleDOI
Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996
Sundaram Hariharan,Christopher P. Johnson,Barbara A. Bresnahan,S. Taranto,Matthew McIntosh,Donald Stablein +5 more
TLDR
There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.Abstract:
Background The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased...read more
Citations
More filters
Journal ArticleDOI
Ciclosporina A e tacrolimus: uma revisão
Solange Cristina Garcia,Luciana dos Santos Lopes,Karen Lílian Schott,Sandra Trevisan Beck,Valdeci Juarez Pomblum +4 more
TL;DR: In this paper, a monitorizacao terapeutica de imunossupressores ciclosporina A (CsA) and tacrolimus (FK506) is presented, with the aim of evitando para o transplantado a perda do enxerto, no caso de baixas doses, ou a toxicidade, em altas doses.
Journal ArticleDOI
Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.
TL;DR: The clinical trials that have evaluated the efficacy and safety of MPA in adult kidney transplantation for the prevention of acute rejection and their use in new combination regimens aiming at minimizing calcineurin inhibitor toxicity and chronic allograft nephropathy are discussed.
Journal ArticleDOI
The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
TL;DR: In this article, an economic evaluation was conducted alongside a multicentre international trial of basiliximab and no statistically significant differences were found in the mean cost of treatment per patient, with a mean difference of $1,660 (95% confidence interval (CI): −$4,150, $7,360; P=0.58).
Journal ArticleDOI
Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study.
Anders Åsberg,Pål Falck,Liv H. Undset,Christina Dörje,Hallvard Holdaas,Anders Hartmann,Karsten Midtvedt +6 more
TL;DR: The computer-assisted TDM-targeted CsA blood concentrations significantly better than experienced transplant physicians are compared, and a possible favorable effect on short- and long-term outcome needs to be verified in further, properly powered, clinical trials.
Journal ArticleDOI
Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
TL;DR: D dosage reduction or discontinuation of mycophenolate mofetil in the first 6 months after diagnosis of GI complications is associated with significantly increased risk of graft failure and increased healthcare costs in adult renal transplant recipients.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TL;DR: This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
Journal ArticleDOI
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Journal ArticleDOI
Risk factors for chronic rejection in renal allograft recipients.
P. S. Almond,A. J. Matas,K. J. Gillingham,David L. Dunn,William D. Payne,Paul F. Gores,Rainer W.G. Gruessner,J. S. Najarian +7 more
TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.
Related Papers (5)
The Banff 97 working classification of renal allograft pathology
Lorraine C. Racusen,Kim Solez,Robert B. Colvin,Stephen M. Bonsib,Maria Castro,Tito Cavallo,Byron P. Croker,A. Jake Demetris,Cynthia B. Drachenberg,Agnes B. Fogo,Peter N. Furness,Lillian W. Gaber,Ian W. Gibson,Dennis Glotz,J. Goldberg,Joseph P. Grande,Philip F. Halloran,H.E. Hansen,Barry Hartley,Pekka Hayry,Claire M. Hill,Ernesto O. Hoffman,Lawrence G. Hunsicker,Anne S. Lindblad,Niels Marcussen,M. J. Mihatsch,Tibor Nadasdy,Peter Nickerson,T. Steen Olsen,John C. Papadimitriou,Parmjeet Randhawa,David C. Rayner,Ian S.D. Roberts,Stephen Rose,D. Rush,Luis Salinas-Madrigal,Daniel R. Salomon,Stale Sund,Eero Taskinen,Kiril Trpkov,Yutaka Yamaguchi +40 more